Literature DB >> 3527076

Dermatologic applications of cyclosporine.

C A Biren, R J Barr.   

Abstract

It is evident that cyclosporine A is a potent immunosuppressive agent and may become immensely valuable in the treatment of cutaneous disease. The extent of its application and efficacy is speculative, as neither the pathogenesis of many of the diseases, nor the mechanism of action of cyclosporine is fully understood. Well-designed clinical and laboratory studies are necessary to delineate its therapeutic value in a particular disorder. It must be emphasized that the systemic use of the drug is associated with several serious side effects, including nephrotoxicity and lymphoproliferative disease. Local topical application may reduce these concerns, and make treatment of benign diseases a possibility. Therefore, until these well-designed prospective studies are performed, cyclosporine's use should be limited and closely monitored.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3527076

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  8 in total

1.  Effects of topical cyclosporin A on guinea-pig toxic contact dermatitis.

Authors:  M Yokoo; D Oka; S Nakagawa
Journal:  Arch Dermatol Res       Date:  1990       Impact factor: 3.017

2.  Psoriasis, cyclosporin A, and AIDS.

Authors:  R C Staughton; A C Keat; J I Harper
Journal:  Br Med J (Clin Res Ed)       Date:  1987-01-10

Review 3.  Recent advances in cyclosporine drug delivery: challenges and opportunities.

Authors:  Dhrumi Patel; Sarika Wairkar
Journal:  Drug Deliv Transl Res       Date:  2019-12       Impact factor: 4.617

4.  Cyclosporin A induced augmentation of the beta-adrenergic adenylate cyclase response of pig epidermis.

Authors:  N Kato; K M Halprin; J R Taylor; A Ohkawara
Journal:  Arch Dermatol Res       Date:  1988       Impact factor: 3.017

5.  Additive and synergistic antiproliferative effects of cyclosporin A and gamma interferon on cultured human keratinocytes.

Authors:  B J Nickoloff; G J Fisher; R S Mitra; J J Voorhees
Journal:  Am J Pathol       Date:  1988-04       Impact factor: 4.307

6.  Effect of cyclosporins A, G, and H on normal and ichthyotic keratinocyte growth in culture.

Authors:  C Amsellem; M Haftek; J Kanitakis; J Thivolet
Journal:  Arch Dermatol Res       Date:  1992       Impact factor: 3.017

7.  Severe atopic eczema: response to oral cyclosporin A.

Authors:  R A Logan; R D Camp
Journal:  J R Soc Med       Date:  1988-07       Impact factor: 18.000

8.  Therapeutic Efficacy of Combination Therapy Using Oral Cyclosporine with a Dietary Supplement (Pantogar®) in Twenty-Nail Dystrophy.

Authors:  Su Jin Oh; Jeong Eun Kim; Joo Yeon Ko; Young Suck Ro
Journal:  Ann Dermatol       Date:  2017-08-25       Impact factor: 1.444

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.